Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 113

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 113
---
 in thousands

NOTE 1:- GENERAL

On December 17, 2024, the Company completed the redomicile from the State of Delaware to the State of Nevada (the “Reincorporation. As a result of the Reincorporation, the Company ceased its business existence as a Delaware corporation and continued its business existence as a Nevada corporation under the name “Revium Rx.”

In November 2023, the Successor entered into the stock exchange agreement with a private Israeli company engaged in the development of novel pharmaceutical solutions. Following the closing of such agreement on July 23, 2024, such Predecessor became a new wholly owned subsidiary of the Company, and as determined by the Company’s board of directors, the business of such Predecessor became the primary focus of the Company’s business, see Note 4. Following the closing of the Share Exchange Agreement, the Company’s Board of Directors determined to discontinue all of the Company’s prior activities and efforts with respect to the development and activation of the clinical decision-making support system, and that the Company will focus on the development of the acquired LipoVation’s (or "Predecessor") business, while allocating a portion of available Company’s resources to the acquisition of additional healthcare or healthcare-related technologies, all with a view to increasing shareholder value.

Prior to the closing of the exchange agreement, the Company had been developing clinical decision-making support system (DMSS) in the field of mental health, including novel diagnostics algorithm and treatment monitoring tools.

| b. | Liquidity             
 and management plans: |

Successor

The Company is in the research and development (R&D) stage and, as such, has not generated any revenues from its current operations. The Company's activities are primarily funded through investment. As of September 30, 2024, the Company reported an accumulated deficit of $10,199.

To support its operations and advance its development programs, the Company intends to continue securing investments. Management anticipates that additional capital will be necessary to fund its ongoing R&D activities and to explore opportunities for acquiring healthcare or healthcare-related technologies. However, there are currently no binding commitments for further investment, and there can be no assurance that the Company will secure the required capital on commercially reasonable terms, or at all.

If sufficient investment cannot be obtained, the Company may need to implement cost-cutting measures, scale back its R&D activities, or delay certain development programs. Despite these potential challenges, management and the board of directors believe that the Company’s existing